For research use only. Not for therapeutic Use.
PF-3845（Cat No.:I000714）is a highly selective and irreversible inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for degrading endocannabinoids like anandamide. By inhibiting FAAH, PF-3845 increases the levels of endocannabinoids, leading to enhanced activation of cannabinoid receptors, which play key roles in regulating pain, mood, and inflammation. PF-3845 has been extensively studied for its analgesic, anti-inflammatory, and neuroprotective effects, showing promise in pain management and neurological disorders. Its ability to modulate the endocannabinoid system makes it a valuable tool in both therapeutic research and drug development.
| Catalog Number | I000714 |
| CAS Number | 1196109-52-0 |
| Synonyms | N-pyridin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide |
| Molecular Formula | C24H23F3N4O2 |
| Purity | ≥95% |
| Target | FAAH |
| Solubility | DMSO ≥90mg/mL Water <1.2mg/mL Ethanol ≥90mg/mL |
| Storage | 3 years -20℃ powder |
| IC50 | 0.23 uM |
| IUPAC Name | N-pyridin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide |
| InChI | InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32) |
| InChIKey | NBOJHRYUGLRASX-UHFFFAOYSA-N |
| SMILES | C1CN(CCC1CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=CN=CC=C4 |
| Reference | </br>1:The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Tchantchou F, Tucker LB, Fu AH, Bluett RJ, McCabe JT, Patel S, Zhang Y.Neuropharmacology. 2014 Oct;85:427-39. doi: 10.1016/j.neuropharm.2014.06.006. Epub 2014 Jun 14. PMID: 24937045 Free PMC Article</br>2:The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, Boger DL, Cravatt BF, Lichtman AH.Br J Pharmacol. 2012 Apr;165(8):2485-96. doi: 10.1111/j.1476-5381.2011.01445.x. PMID: 21506952 Free PMC Article |
